Cogent Biosciences(COGT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-4859, a reversible, potent, selective, FGFR2 inhibitor SUMMIT and APEX clinical presentations at upcoming ASH annual meeting Strong cash position of $346 million suf icient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., November 12, 2024 – Cogent Biosciences, ...